The REST study: isatuximab-bortezomib-lenalidomide in elderly patients with myeloma
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, provides insight into the REST study (NCT04939844) and comments on what the results demonstrate about the feasibility of using a combination of isatuximab, bortezomib, and lenalidomide in elderly patients with multiple myeloma (MM). Patients in the trial had a median age of 77 years and a measurable residual disease rate (MRD)-negativity rate of 38% after 18 cycles was achieved. Therefore, this study demonstrates a viable approach to using the treatment regimen of the IMROZ trial (NCT03319667) in elderly and frail patients by removing dexamethasone. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
